Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 212

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype

Lowery, Maeve A., Jordan, Emmet J., Basturk, Olca, Ptashkin, Ryan N., Zehir, Ahmet, Berger, Michael F., Leach, Tanisha, Herbst, Brian, Askan, Gokce, Maynard, Hannah, Glassman, Danielle, Covington, Christina, Schultz, Nikolaus, Abou-Alfa, Ghassan K., Harding, James J., Klimstra, David S., Hechtman, Jaclyn F., Hyman, David M., Allen, Peter J., Jarnagin, William R., Balachandran, Vinod P., Varghese, Anna M., Schattner, Mark A., Yu, Kenneth H., Saltz, Leonard B., Solit, David B., Iacobuzio-Donahue, Christine A., Leach, Steven D., O'Reilly, Eileen M. · 2017 · Clinical Cancer Research

Abstract

Purpose: Molecular profiling in cancer has identified potential actionable drug targets that have prompted attempts to discover clinically validated biomarkers to guide therapeutic decision-making and enrollment to clinical trials. We evaluated whether comprehensive genetic analysis of patients with pancreatic adenocarcinoma is feasible within a clinically relevant timeframe and whether such analyses provide predictive and/or prognostic information along with identification of potential targets for therapy. Experimental Design: Archival or prospectively acquired FFPE samples and matched normal DNA from N = 336 patients with pancreatic cancer were analyzed using a hybridization capture–based, next-generation sequencing assay designed to perform targeted deep sequencing of all exons and selected introns of 410 key cancer-associated genes. Demographic and treatment data were prospectively collected with the goal of correlating treatment outcomes and drug response with molecular profiles. Results: The median time from protocol consent to reporting of the genomic results was 45 days with a median time from tissue delivery of 20 days. All genetic alterations identified were stratified based upon prior evidence that the mutation is a predictive biomarker of drug response using the MSKCC OncoKB classification. Three of 225 patients (1%) received a matched therapy based upon the sequencing results. Conclusions: The practical application of molecular results to guide individual patient treatment is currently limited in patients with pancreatic adenocarcinoma. Future prospective molecular profiling efforts should seek to incorporate routine germline genetic analysis and the identification of DNA profiles that predict for clinical benefit from agents that target DNA damage repair and or immunotherapy. Clin Cancer Res; 23(20); 6094–100. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-0899

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 212

Metadata

Authors
Lowery, M. A., Jordan, E. J., Basturk, O., Ptashkin, R. N., Zehir, A., Berger, M. F., Leach, T., Herbst, B., Askan, G., Maynard, H., Glassman, D., Covington, C., Schultz, N., Abou-Alfa, G. K., Harding, J. J., Klimstra, D. S., Hechtman, J. F., Hyman, D. M., Allen, P. J., Jarnagin, W. R., Balachandran, V. P., Varghese, A. M., Schattner, M. A., Yu, K. H., Saltz, L. B., Solit, D. B., Iacobuzio-Donahue, C. A., Leach, S. D., & O'Reilly, E. M.
Venue
Clinical Cancer Research
Published
2017-10-12
Volume
23
Issue
20
Pages
6094-6100
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2740722982
Cited by
212
References
5
FWCI
7.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-0899
The paper
Lowery, M. A., Jordan, E. J., Basturk, O., Ptashkin, R. N., Zehir, A., Berger, M. F., Leach, T., Herbst, B., Askan, G., Maynard, H., Glassman, D., Covington, C., Schultz, N., Abou-Alfa, G. K., Harding, J. J., Klimstra, D. S., Hechtman, J. F., Hyman, D. M., Allen, P. J., . . . O'Reilly, E. M. (2017). Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-0899

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.